A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

NCT05849662 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Juvenile Myelomonocytic
JMML
JCML
Neurofibromatosis 1
CBL Syndrome

Interventions

DRUG: Trametinib
DRUG: Azacitidine
DRUG: Fludarabine
DRUG: Cytarabine

Sponsor

Therapeutic Advances in Childhood Leukemia Consortium